HIV-1 were cultivated in medium containing excess concentrations of these drugs, and the drug susceptibilities of the breakthrough viruses recovered from the medium were measured. Although nevirapine lost its antiviral activity after six passages, a delay in the emergence of fully resistant viruses was observed for MKC-442. Two resistant clones for each drug were isolated and nucleotide sequences within the RT region were analysed. An amino acid substitution at position 181 (Tyr to Cys) was found, with additional substitutions at positions 103 (Lys to Arg) and 108 (Val to lie) in the MKC-442-resistant viruses. These clones showed various susceptibilities to MKC-442, and cross-resistance to other NNRTls but not to AZT. These results suggest that the major binding site of MKC-442 on the HIV-1 RT is the tyrosine residue common to these NNRTls, and that drug resistance to NNRTls is dependent on both the quality and the quantity of mutations within the HIV-1 RT gene.
Introduction
The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is essential for viral infectivity (Barre-Sinoussi et al., 1983; Popovic et al., 1984) . Different classes of HlV-1 RT inhibitors have been reported as anti-HIV-1 agents. Nucleoside analogues such as 3'azldo-a-deoxythymldine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'-dideoxycytidine (ddC), and 2',3'-didehydro-3'-deoxythymidine (d4T) are the only drugs currently approved for anti-HIV therapy. These agents have been shown to act as potent inhibitors of HIV-1 RT after triphosphorylation in the infected cells (Mitsuya et al., 1990) . However, cellular activation is not required for inhibition by non-nucleoside RT inhibitors (NNRTls) (De Clercq, 1992) . which include 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio)thymine (HEPT) Baba et al., 1989) and its derivatives (Baba et al., 1991a,b) , tetrahydroimidazo [4,5,1-jk] [1,4]-benzodiazepine-2(1H)-tliione (R82,913) (Pauwels et al., 1990), 6,11-dihydro-11-cyclopropyl-4-methyldipyrido [2,3-b:2',3'-eH1,4] diazepine-6-one (nevirapine) (Merluzzi et al., 1990; Richman et al., 1991a) , the pyridinone derivative 3-[2-(benzoxazol-2-yl)ethyl]-5-ethy·6-methylpyridine-2(1Hi-one (L-696229) (Goldman et al., 1991) , and bis(heteroaryl) piperazines (BHAPs) (Romero et al., 1991) . These NNRTls are highly specific HIV-1 RT inhibitors which are not active against other retroviral RTs, including HIV-2 RT. Since their mode of action is allosteric inhibition, their binding sites are thought to differ from those of nucleotide substrates (Frank et al., 1991; Wu et al., 1991; Debyser et al., 1992; Tramontano and Cheng, 1992) . From an X-ray structural analysis of the nevirapine HIV-1 RT complex, the binding site was determined to be a hydrophobic pocket next to the catalytic site (Kohlstaedt et al., 1992) .
The emergence of drug-resistant variant virus is a major concern in anti-HIV therapy. In prolonged treatment with AZT of patients with acquired immune deficiency syndrome (AIDS), HIV-1 variants with reduced AZT susceptibility were frequently isolated (Larder et al., 1989; Land et al., 1990) . Although the pathogenic importance of these isolates has not been proven, it is likely that break-through of the resistant virus makes the drug less effective. Viruses resistant to NNRTls were also isolated from patients who received nevirapine (M. E. van der Ende, M. Loewenthal and M. D. de Jong, unpublished results). Similarly, drug-resistant variants have been selected by cultivation of virus in the presence of the inhibitors (Larder et al., 1991) . It has been noted that emergence of drugresistant variant virus occurs more rapidly in treatment with nevirapine than in that with AZT (Richman et al., 1991b; Mellors et al., 1992) . In this study, we investigated the process of the emergence of virus resistant to MKC-442 in comparison to the emergence of virus resistant to nevirapine. From the fully resistant Virus culture, drugresistant clones were isolated and their susceptibilities to NNRTls were examined. Their nucleotide sequences were analysed in order to identify the key amino acids involved in the binding of MKC-442 to the RT molecule.
Results

Passages of HIV-1 with increasing concentrations of anti-HIV-1 agents
A clinical isolate, HIV-1 (HE), was used to establish drugresistant variants. To produce a selection pressure on HIV-1 replication, compound concentrations 2.5 times higher than the EC so values of the compounds for the parent virus were used in virus passages. After three passages, the drug susceptibility of each breakthrough virus was measured. Since there was no significant difference in drug susceptibility betiNeen the zeroth and the third passages (Table 1) , concentrations of the compounds were further increased (5 x EC so ) over the next three passages. The concentrations used were 0.1, 0.65 and 0.0165 J.lM for MKC-442, nevirapine and AZT, respectively. Although the susceptibility to AZT was unchanged, the breakthrough viruses proved to be much less susceptible to MKC-442 and nevirapine than their parents after three additional passages ( Table 1 ). The EC so value of nevirapine for the virus recovered after the sixth passage was not determined, but it was estimated to be more than 40 J.lM because nevirapine inhibited only 13% of the viral replication at a concentration of 20 J.lM. CC so values were also determined, and selectivity indices (Sis) were calculated by dividing CC so values by EC so values. Fig. 1 shows the change in SI for three anti-HIV-1 agents over nine passages. From this figure it is clear that nevirapine efficacy was virtually non-existent after the sixth passage.
Although the efficacy of MKC-442 diminished between the third and sixth passages, there was still moderate anti-HIV-1 activity (EC so = 2.1 J.lM) after the sixth passage (Table 1) . After nine passages, MKC-442 was almost ineffective, and complete resistance to nevirapine was confirmed ( Fig. 1 ). During these passages, significant reduction of the efficacy of AZT was not observed (Table 1) .
Isolation of drug-resistant clones of HIV-1
Two clones were isolated from each culture supernatant after nine passages using a limiting dilution method, and were examined for their susceptibility to MKC-442, nevirapine, L-696229 and AZT. The clones isolated from the cell culture in the presence of MKC-442 are designated HE 44 2 -1 and HE 4 4 2 -2 ; those isolated in the presence of nevirapine are designated HE NEV-1 and HE NEV-2 ' HE 44 2 -1 was 5500-fold less susceptible to MKC-442 than its parent strain HE, while HE 4 4 2 -2 was completely resistant to the compound (Table 2) . These clones were also completely resistant to nevirapine and L-696 229, and yet their susceptibilities to AZT were equal to or slightly higher than that of the HE strain (Table 2) . Although HE NEV-1 and to GAT) in both strains, at position 210 Leu (TTA to DG) in HE N EV • 1 ' and at position 231 Gly (GGT to GGC) in HE NEV -2 (data not shown).
Marked differences in amino acid sequence were observed between the two MKC-442-resistant clones. The highly resistant clone, HE 4 42 -2 , was shown to have a second amino acid change (Lys to Arg) at position 103 resulting from double' mutations in the nucleotide sequences (AAA to AGG). This mutation was not identified in HE 4 42 -1 , but another "Imino acid change (Val to lie) was found at position 108 as a result of a purine transition of the first codon (GTA to ATA). HE NEV -2 displayed full resistance to nevirapine and L-696229, MKC-442 could inhibit the replication of these clones ( Among the NNRTls reported, MKC-442 is one of the strongest inhibitors of HIV-1 replication (Saba et al., 1993) . Since MKC-442 has a high specificity for HIV-1 RT and is much less toxic to bone marrow cells than AZT, it is recognized as a promising therapeutic agent against AIDS (Saba et al., 1993; Tanaka et al., manuscript in preparation) . For NNTRls, the emergence of drug-resistant virus during therapy is a major concern; the efficacy of nevirapine, for example, was shown to decrease rapidly in vitro and in vivo (Richman et al., 1991b; Mellors et al., 1992;  619-bp fragments of the N-terminal region of the HIV-1 RT gene were obtained from five different clones. For compatibility (Larder et al., 1989; Goldman et al., 1991) , the 5'-end nucleotide of the fragments was designated 107 (nucleotide A) and the NH 2-terminal amino acid Was assigned the number 58 (codon AD). The sequences of the amplified genes were primarily determined by a direct sequencing method using amplified cDNA fragments. Nucleotide sequences were further confirmed in three independent cDNA clones for each virus strain. The amino acid sequences of the N-terminal RT genes are summarized in Fig. 2 . In HE N EV -1 and HE N EV -2 , a single transition of the second base (A to G) of the 181th codon was observed, leading to an amino acid change from Tyr to Cys. This mutation was also seen in HE 4 4 2 -1 and HE 4 42 -2 . Although no other amino acid substitution was found in the sequenced domain of the nevirapineresistant clones, some nucleotide transitions without amino acid changes were found at position 177 Asp (GAC M. E. van der Ende et el., unpublished results). The purpose of our study was to evaluate the resistance profile of MKC-422 and to identify key amino acids responsible for its binding to HIV-1 RT before starting clinical studies of this compound. HIV-1 variants with reduced susceptibility to MKC-442 and nevirapine were selected using a clinical isolate, HIV-1 (HE), and an in vitro culture system under the pressure of excess concentrations of the compounds.
Nucleotide sequence analysis of RT genes of HIV-1 mutants
A reduction in susceptibility to nevirapine was observed after only six passages, and a single mutation of Tyr181---7Cys was found in two nevirapine-resistant clones isolated from the ninth passage, in which complete resistance to nevirapine was established. The emergence of complete resistance was slower for MKC-442 than for nevirapine, although significant resistance to either MKC-442 or nevi rapine was observed at the sixth passage. Various kinds of resistant clone were expected to be present at this passage, especially in the case of MKC-442. If the major population was the single amino acid mutant of Tyr181---7Cys in the MKC-442-resistant clones, its percentage was about 20% as calculated from the susceptibility data of Tables 1 and 2. Supposing that the SI of a completely resistant clone is equal to 1, the population of clones completely resistant to nevirapine (HE N EV _ 1 or HE N E V -2 in Table 2 ) was calculated to be around 25% at the sixth passage (Fig. 1) . The similarity between these values suggested that the rate of acquisition of a single mutation for drug resistance was the same for the two drugs. The difference between MKC-442 and nevirapine in the emergence of completely resistant viruses could result from the difference between the two drugs in the number of mutations required for complete resistance. Resistance to MKC-442 required two mutations in the RT molecule, while resistance to nevirapine required only one (Table 2 and Fig. 2 ). Since MKC-442 is a highly potent NNRTr, multiple steps would be necessary for the acquisition of complete resistance. These findings suggested that the slower emergence of virus completely resistant to MKC-442 was mainly derived from the higher antiviral activity of MKC-442 against HIV-1, in comparison to that of nevirapine.
The substitution at position 181 (Tyr to Cys) mentioned above was identical to the substitution in nevirapine-resistant clones previously reported by Richman et al. (1991b) and Mellors et al. (1992) . In addition, another strain resistant to MKC-442 was selectively obtained from HTLV-III B , and the same single mutation was found in its RT gene (Baba et al., 1993) . Since this mutation reduced the efficacy of both nevirapine and L-696229, cross-resistance among the NNRTls was confirmed. Thus, the mutation of amino acid 181 is probably responsible for the resistance of the NNRTls. However, we identified two additional mutations in the RT region of MKC-442-resistant strains. They are 103 (Lys---7Arg) and 108 (Val-elle), which are located in a~-sheet of amino acid residues 100-108 which forms the binding pocket for NNRTls, together with another~-sheet of amino acid residues 181-190 which is recognized as a catalytic site (Kohlstaedt et al., 1992) . As shown previously (Balzarini et al., 1993a,b) , different amino acid substitutions of RT generate different patterns of susceptibility to NNRTls. The amino acid change at position 103 (Lys-e Asn) was known to occur in combination with the 181 change in a resistant virus of L-693593, a compound closely related to L-696229 (Goldman et al., 1991) . Site-directed mutagenesis of HIV-1 RT revealed that the 103 mutation conferred weaker resistance to L-696229 than the 181 mutation, but that the HIV-1 variant with the 103 mutation had 20 times lower susceptibility to L-696229 than the parent virus (Byrnes et el., 1993) . According to Boyer et et. (1993) , a double-mutated HIV-1 RT was almost completely resistant to HEPT, the lead compound of MKC-442, in contrast to the partial resistance of single-mutated RTs. In addi· tion, one of the MKC-442-resistant clones, HE 4 4 2 -2 , which is a double mutant, was highly resistant to MKC-442, nevirapine and L-696229 (Table 2) . Thus, viruses having both the 103 and the 181 mutations were highly resistant to some NNRTls. On the other hand, mutations at position 108 brought about a minor change in the susceptibility to NNRTls; for L-693593, L-696229, nevirapine and TIBO, the EC so values for HIV-1 RT activity were only slightly higher than those for the wild-type RT (Boyer et el., 1993) . As shown in Table 2 , HE 4 4 2 -1 , a resistant clone which had both the 108 and the 181 mutations, was less resistant to MKC-442 than HE 4 4 2 -2 but was significantly more resistant than either of the nevirapine-resistant clones with the 181 mutation (Table 2 ). These data revealed that drug resistance to NNRTls was dependent on both the quality and the quantity of mutations within the HIV-1 RT gene.
Viruses resistant to HEPT derivatives other than MKC-442 were recently isolated and characterized (Balzarini et al. 1993c ). An amino acid substitution at position 188 (Tyr-el-lls), 181 (Tyr---7Cys) or 106 (Val---7Ala) was found within the amino acid region 50-270 of a clone resistant to HEPT, E-EBU (6-benzyl-1-ethoxymethy-5-ethyluracil) or E-EBU-dM (6-[3,5-dimethyl]benzyl-1-ethoxymethy-5ethyluracil), respectively. Although these amino acid substitutions were known in other NNRTls (Schinazi et el., 1994) , there were certain differences in the preferred position for drug resistance between the HEPT derivatives. Such differences in the substitution positions may reflect a subtle difference in the site of binding to the HIV-1 RT molecule.
A possible advantage of MKC-442 over nevirapine or other NNRTls has been demonstrated recently (Yuasa et al., 1993) . When the combined inhibitory effects of NNR-Tis with AZT-triphosphate on HIV-1 RT activity were com-pared, MKC-442 showed.strong synergism. In contrast, a weakly synergistic or additive effect was observed with the comb,ination of nevirapine and AZT-triphosphate. Combination therapy using AZT and MKC-442 is therefore an attractive approach for the treatment of AIDS. Furthermore, the combination may reduce the emergence of drug-resistant virus (De Clercq, 1992) . To examine this possibility, long-term cultivation of HIV-1 with single or combined anti-HIV-1 agents was carried out. Simultaneous treatment with MKC-442 (28 nM) and AZT (8 nM) prevented the breakthrough of HIV-1 in MT-4 cells for more than 60 days (M. Baba et al., unpublished results) . Although Larder et al. (1993) demonstrated a rapid emergence of HIV-1 co-resistance to AZT, ddl and nevirapine in an MT-2 cell culture starting from a virus doubly resistant to AZT and ddl, it was found that the triply resistant virus had a mutation at position 106 rather than 181. Byrnes et al. (1993) reported that site-directed mutagenesis of H IV-1 RT at position 106 did not reduce the efficacy of some NNRTls, suggesting that this amino acid substitution is a minor mutation for re~istance to NNRTls. In addition, we obtained an HIV-1~riant co-resistant to MKC-442 and AZT when the selection started from an AZT-resistant strain (A018C). The co-resistant mutant was found to have three amino acid substitutions in the RT (at positions 74, 103 and 108) in addition to those in A018C. Interestingly, it exhibited a several-fold increase in susceptibility to both AZT and ddl, in spite of a 200·fold decrease in susceptibility to unpublished results) . It is therefore very probable that the combination of MKC-442 with AZT (or other dideoxynucleosides) can be used as an effective chemotherapy for AIDS.
Materials and Experimental Procedures: Chemistry
MKC-442 was prepared as described elsewhere (Tanaka et al., manuscript in preparation) . AZT was purchased from Sigma Chemical Co. (St Louis, MO). Nevirapine and the pyridinome derivative 3-[2-(benzoxyazol-2-yl)ethyl]-5-ethyl-6-methylpyridine-2(1 H)-one (L-696229) were synthesized as described elsewhere (Hargrave et al., 1991; Mantlo et al., 1991) . All compounds were dissolved in dimethyl sulfoxide and stored at -20°C until used.
Materials and Experimental Procedures: Virology
Cells and viruses
MT-4 cells weregrown and maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf-serum, 100 U penicillin G rnl ", and 100 Ilg streptomycin rnr" (Miyoshi et al., 1982) . HIV-1 (HE) was a clinical isolate from a Belgian AIDS patient (Pauwels et al., 1990) . HIV-1 (Ills) was kindly provided by Drs R.C. Gallo and M. Popovic (National Cancer Institute, Bethesda, MD) . Titres of virus stocks were determined in MT-4 cells, and stored at -80°C until used.
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Assays of susceptibility of HIV-1 strains to anti-HIV agents
The susceptibility of HIV-1 strains to anti-HIV-1 agents was assessed by the inhibition of virus-induced cytopathic effect in MT-4 cells. Briefly, MT-4 cells (1 xi 0 4 cells/well) in microtitre plates were infected with HIV-1 strains at a multiplicity of infection (MOl) of 0.02 and cultured in the presence of varying concentrations of the test compounds. After a 4-day incubation at 37°C, the number of viable cells was measured by the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (Pauwels et al., 1988) . The cytotoxicities of the compounds were evaluated in parallel with their anti-HIV-1 activities and were based on the viability of mock-infected MT-4 cells as determined by the MTT method. The 50% effective concentrations (EC so ) and 50% cytotoxic concentrations (CC so ) of the compounds were calculated from dose-response curves.
Passages of HIV-1 with increasing concentrations of anti-HIVagents
MT-4 cells (1 x to" cells mr') were infected with HIV-1 (HE) at a MOl of 0.02. The infected cells were cultured in the presence of concentrations of the test compounds 2.5 times higher than their EC so values. After a 4-day incubation at 37°C, the cells were subcultured at a ratio of 1 : 10 with fresh culture medium containing the same concentrations of the compounds. After the third passage, the virus titre of the culture supernatants was determined. The susceptibility of the virus to the compounds was re-evaluated to obtain new EC so values. From the fourth to the sixth and from the seventh to the ninth passage, these procedures were repeated with the exception that drug concentrations were 5 times higher than the EC so values to increase the selection pressure of the drugs.
Isolation of drug-resistant variants of HIV-1
After the ninth passage, cloning of the drug-resistant variant was carried out using a limiting dilution method. The virus was propagated in MT-4 cells (1 x10 s cells mr'), and the culture supernatants were collected and used as the viral stocks when a complete cytopathic effect was shown. The sensitivity of the HIV-1 clones to the test compounds was determined by the MTTmethod.
PCR amplification of HIV-1 mutant DNA within the RT region
Viral RNA was extracted from 200 III of the viral stock using a guanidine/cesium chloride method (Chromozynski and Sacchi, 1989) . After purification of the RNA by phenol/chloroform extraction, cDNA was synthesized by adding 2.5 units of Moloney murine leukemia virus RT and 50 pmol of random hexamer per Ill. The cDNA was then amplified by a standard PCR method (Saiki et al., 1987) with 0.5 11M of a sense primer (SY5, 5'-CGTAGAATTCTTGGGCCTGAAAATCCA-3') and an antisense primer (SY6, 5'-TGACGTCGACTCATTGACAGTC-CAGCT-3') to obtain a 619-bp fragment involving nucleotides 2697-3315 of the HIV-1 (HXB2) isolate (accession number K03455) (Ratner et al., 1985) . The PCR reaction mixture was heated at 94°C for 5 min before addition of Taq polymerase (Perkin Elmer Cetus, Norwalk, CT). Amplification was started by denaturing the cDNA target at 93°C for 1 min, annealing primers at 55°C for 1 min and extending primers at 72°C for 2 min. This temperature profile formed one cycle and was repeated 30 times. The amplified product was purified by 5% acrylamido gel electrophoresis, treated with T4 polymerase and T4 polynucleotide kinase, and then inserted into the Smal site of pUC19. Three independent clones were isolated.
Nucleotide sequence analysis of RT genes of HIV-1 mutants
For direct sequence analysis, two kinated primers were prepared by phosphorylating SY5 and SY6 primers. The HIV-1 cDNAs 1 were amplified using a set of primers (Le. one kinated primer and one intact primer). The PCR fragments obtained were digested by A exonuclease to produce single-stranded DNA molecules (Higuchi and Ochman, 1989) , which were directly sequenced using the Genesls" 2000 DNA Analysis System (Du Pont, Boston, MA). The cloned DNAs in pUC19 were also analysed for their nucleotide sequences as doublestranded DNA using a Taq Dye DeoxyTM Terminator Cycle sequencing kit (Applied Biosystems, Foster City, CAl and a Model 373A DNA sequencer (Applied Biosystems, Foster City, CAl·
